Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,188 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Upper Extremity Clear all
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

NCT03434119
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
85
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 25, 2026, 10:16 PM EDT
Terminated Phase 2 Interventional Results available

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

NCT00661531
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast, Neoplasms, Breast
Interventions
Estrace, Anastrozole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 2 Interventional

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

NCT00001095
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Amprenavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Broad Band Light for the Treatment and Prevention of Senile Purpura

NCT03690375
View directory record Official record
Conditions
Senile Purpura, Bateman's Purpura
Interventions
Broad Band Light (BBL)
Device
Lead sponsor
Siperstein Dermatology
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 25, 2026, 10:16 PM EDT
Recruiting Not applicable Interventional

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812
View directory record Official record
Conditions
Breast Cancer, High Risk of Breast Cancer
Interventions
da Vinci SP Surgical System
Device
Lead sponsor
Deborah Farr, MD
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 10:16 PM EDT
Recruiting Phase 2 Interventional

Human Upper Extremity Allotransplantation

NCT01459107
View directory record Official record
Conditions
Amputation, Traumatic, Wounds and Injuries, Hand Injuries
Interventions
Deceased donor hand transplantation, Bone marrow cell-based therapy & single-drug immunosuppression.
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 69 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2036
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 10:16 PM EDT
Terminated Not applicable Interventional

RSA vs. Nonop for 3 & 4-Part Proximal Humerus Fractures

NCT03599336
View directory record Official record
Conditions
Humerus Fracture, Humerus, Shoulder Fractures, Shoulder Arthropathy Associated With Other Conditions, Arthropathy Shoulder, Shoulder Injury, Arthropathy
Interventions
Reverse Total Shoulder Arthroplasty (rTSA), Nonoperative Treatment
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144
View directory record Official record
Conditions
Chronic Severe Plaque-type Psoriasis
Interventions
Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 25, 2026, 10:16 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Blood Glucose Differences Between Left Arm and Right Arm Using a Continuous Glucose Monitor

NCT04102657
View directory record Official record
Conditions
Diabetes
Interventions
Intermittent Fasting, Free-Living Diet, Left Arm Exercise, Right Arm Exercise
Other
Lead sponsor
University of the Pacific
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 25, 2026, 10:16 PM EDT
Not yet recruiting Not applicable Interventional

Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA).

NCT07613281
View directory record Official record
Conditions
Snoring, OSA - Obstructive Sleep Apnea
Interventions
Palatal Implant System
Device
Lead sponsor
Serene Sleep, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
San Francisco, California • Evans, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 10:16 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

NCT06878365
View directory record Official record
Conditions
Type 1 Interferonopathies
Interventions
BI 3000202_low dose, BI 3000202_high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 10:16 PM EDT
Withdrawn No phase listed Observational

Oral Steroid Treatment for Chronic Rhinosinusitis

NCT01255683
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
oral corticosteroid taper
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

NCT02452931
View directory record Official record
Conditions
Precocious Puberty, Central
Interventions
Leuprolide Acetate 45 mg
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
2 Years to 9 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
San Diego, California • Hollywood, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

NCT01083602
View directory record Official record
Conditions
Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
Interventions
panobinostat, bortezomib, dexamethasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

EMG Training for Altering Activation Patterns After Stroke

NCT03619772
View directory record Official record
Conditions
Stroke, Weakness, Muscle, Coordination Lack
Interventions
Bilateral, Unilateral
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

NCT00722553
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
Interventions
Pralatrexate Injection, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

NCT00884312
View directory record Official record
Conditions
Multiple Myeloma, Solid Tumors
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
21
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

NCT00782067
View directory record Official record
Conditions
Leukemia
Interventions
Midostaurin (PKC412)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 2 Interventional

3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy

NCT00520702
View directory record Official record
Conditions
Lung Cancer
Interventions
Intensity Modulated Radiation Therapy, 3-Dimensional Conformal Radiation Therapy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 4 Interventional Results available

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

NCT02191137
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
58
States / cities
Tucson, Arizona • La Jolla, California • Moreno Valley, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 1 Interventional

Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration

NCT04673877
View directory record Official record
Conditions
Infection, Hand Injury Wrist, Hand Injuries, Hand Injuries and Disorders, Hand Arthritis
Interventions
Systemic IV Vancomycin, Bier Block, Vancomycin
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 25, 2026, 10:16 PM EDT
Withdrawn Phase 4 Interventional

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

NCT03585101
View directory record Official record
Conditions
Hepatitis C
Interventions
Elbasvir/grazoprevir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 25, 2026, 10:16 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows

NCT00752297
View directory record Official record
Conditions
Glabellar Rhytides
Interventions
Preservative-free Saline, Mentor Purified Toxin
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 25, 2026, 10:16 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 10:16 PM EDT